$IONS

AI Analysis

Generated on May 11, 2026

AI Score
52/ 100
Hold$IONS

Ionis Pharmaceuticals

$IONSNASDAQHealthcareMid-Cap

Ionis pioneers antisense technology to develop RNA-targeted therapeutics for serious diseases.

Market Cap
$7.0B
Revenue (TTM)
$0.8B
+5.0%
Net Income (TTM)
-$0.3B
N/A
EPS (TTM)
-$2.00
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$38-$55
Beta
0.62
Dimension Scores
Fundamental
45
Technical
50
Sentiment
58
Risk / Reward
48
Momentum
58
FundTechSentRiskMome
Financial Health
Profitability
50weak
Growth
61moderate
Liquidity
56strong
Solvency
47moderate
Efficiency
43moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $IONS

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.